Targeting Protein Kinase CK2: Evaluating CX-4945 Potential for GL261 Glioblastoma Therapy in Immunocompetent Mice

By Ferrer-Font Laura   Villamañan Lucia   Arias-Ramos Nuria   Vilardell Jordi   Plana Maria   Ruzzene Maria   Pinna Lorenzo A.   Itarte Emilio   Arús Carles   Candiota Ana Paula  

Pharmaceuticals, Vol. 10, Iss. 1, 2017-02 ,pp. : 24-24

MDPI

Access to resources Recommend Favorite

Synthesis, Biological Evaluation and Molecular Modeling of Substituted Indeno[1,2-b]indoles as Inhibitors of Human Protein Kinase CK2

By Alchab Faten   Ettouati Laurent   Bouaziz Zouhair   Bollacke Andre   Delcros Jean-Guy   Gertzen Christoph G.W.   Gohlke Holger   Pinaud Noël   Marchivie Mathieu   Guillon Jean   Fenet Bernard   Jose Joachim   Le Borgne Marc  

Pharmaceuticals, Vol. 8, Iss. 2, 2015-06 ,pp. : 279-302

MDPI

Access to resources Recommend Favorite

Development of Pharmacophore Model for Indeno[1,2-b]indoles as Human Protein Kinase CK2 Inhibitors and Database Mining

By Haidar Samer   Bouaziz Zouhair   Marminon Christelle   Laitinen Tuomo   Poso Antti   Le Borgne Marc   Jose Joachim  

Pharmaceuticals, Vol. 10, Iss. 1, 2017-01 ,pp. : 8-8

MDPI

Access to resources Recommend Favorite

The Link between Protein Kinase CK2 and Atypical Kinase Rio1

By Kubiński Konrad   Masłyk Maciej  

Pharmaceuticals, Vol. 10, Iss. 1, 2017-02 ,pp. : 21-21

MDPI

Access to resources Recommend Favorite

A π-Halogen Bond of Dibenzofuranones with the Gatekeeper Phe113 in Human Protein Kinase CK2 Leads to Potent Tight Binding Inhibitors

By Schnitzler Alexander   Gratz Andreas   Bollacke Andre   Weyrich Michael   Kuckländer Uwe   Wünsch Bernhard   Götz Claudia   Niefind Karsten   Jose Joachim  

Pharmaceuticals, Vol. 11, Iss. 1, 2018-02 ,pp. : 23-23

MDPI

Access to resources Recommend Favorite